IDEAYA Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by...
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1
IDEAYA Biosciences announces Phase 1 expansion results of IDE397, an oral MAT2A inhibitor for MTAP-deletion urothelial and NSCLC, at the 36th EORTC-NCI-AACR Symposium in Barcelona, Oct. 23-25, 2024. Oral presentation by Dr. Benjamin Herzberg on Oct. 25, 3:00pm CEST, with additional poster presentations on MAT2A and PARG programs.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences granted 140,000 non-qualified stock options to a new employee on September 26, 2024, under the 2023 Inducement Plan, with an exercise price of $30.50 per share, vesting over four years.
Ideaya reports positive interim phase 2 data for darovasertib and successful US FDA Type C
Ideaya Biosciences announced positive phase 2 data for darovasertib in neoadjuvant uveal melanoma, showing 49% tumor shrinkage and 61% eye preservation. The FDA Type C meeting supported eye preservation and time to vision loss as primary endpoints, paving the way for a potential registrational phase 3 trial.
IDEAYA Shares Positive Phase II Data for Darovasertib and Plans for Future Phase III Trial
IDEAYA Biosciences reports positive Phase II data for darovasertib in neoadjuvant uveal melanoma, with 49% of patients showing >30% tumor shrinkage and a favorable adverse event profile. The company plans a Phase III trial with 400 patients, focusing on eye preservation and time to vision loss as primary endpoints.
Related Clinical Trials:
IDEAYA's rare cancer drug shows promise as company lays out Phase III plans
IDEAYA Bioscience's darovasertib, a PKC inhibitor for neoadjuvant uveal melanoma, showed 30% tumor shrinkage in half of patients and 61% eye preservation rate in Phase II trial. The company plans a Phase III trial enrolling 400 patients, with FDA guidance on potential endpoints and broad indication label for high-risk metastatic disease.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib
IDEAYA Biosciences reports positive Phase 2 darovasertib data in neoadjuvant uveal melanoma, with ~49% tumor shrinkage and ~61% eye preservation. A Phase 3 registrational trial is planned following FDA guidance, targeting ~400 patients. Annual incidence of primary UM in North America, Europe, and Australia is ~12k, with no FDA-approved therapies.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and ...
IDEAYA Biosciences reports positive Phase 2 data for darovasertib in neoadjuvant uveal melanoma, with ~49% tumor shrinkage and ~61% eye preservation. A Phase 3 registrational trial is planned following FDA guidance, targeting ~400 patients with potential broad indication for low, intermediate, and high-risk metastatic disease.
Ideaya Biosciences Sees Positive Data From Darovasertib Trial
Ideaya Biosciences reports positive Phase 2 data for darovasertib in neoadjuvant uveal melanoma, with 49% tumor shrinkage and 61% eye preservation. FDA supports eye preservation and time to vision loss as primary endpoints, potentially setting a new standard of care.
© Copyright 2024. All Rights Reserved by MedPath